文献速递药物相互作用治疗药物监测与药物基因组学

咪达唑仑微剂量在早期临床开发中用于药物相互作用评估

Midazolam microdosing applied in early clinical development for drug-drug interaction assessment.
PubMed 文献 · Br J Clin Pharmacol · 2020-06-10

在3项早期临床研究中,将75 μg咪达唑仑微剂量用于评估受试物(化合物A、B、C)对CYP3A的药物相互作用潜力。结果显示,各化合物最高剂量组咪达唑仑AUC0-∞几何均值比范围为92.0%至127.1%,Cmax几何均值比范围相似,未发现相关药物相互作用。AUC2-4比值与AUC0-∞比值相当,提示咪达唑仑微剂量结合有限采样可减少受试者负担及专项药物相互作用研究。

要点

  • 75 μg咪达唑仑微剂量可在所有受试者中完整定量暴露。
  • 化合物A、B、C最高剂量组AUC0-∞几何均值比为92.0%–127.1%,未见相关DDI。
  • AUC2-4比值与AUC0-∞比值相当,支持有限采样。

核心结论

  • 将咪达唑仑微剂量纳入早期临床研究是减少专项药物相互作用研究的可行工具,可降低受试者负担。
  • 有限采样可进一步减少受试者负担、成本及所需资源。

研究设计与样本

  • 开展3项早期临床研究,受试物为化合物A、B和C,这些化合物在体外给出阳性CYP3A perpetrator信号。
  • 单用75 μg咪达唑仑作为基线CYP3A活性,随后在与各化合物最高剂量组联合给药的第1/3天和第14或17天重复给予咪达唑仑。
  • 通过方差分析对对数转换数据比较咪达唑仑暴露(AUC0-∞、Cmax),并用线性回归对对数转换数据比较部分AUC2-4比值与AUC0-∞比值。

主要发现

  • 测试化合物的Cmax值超过药物相互作用潜力的相关阈值。
  • 所有研究中所有受试者的咪达唑仑浓度可在完整 профиле 中定量。
  • 咪达唑仑AUC0-∞几何均值比点估计:化合物A为108.3%–127.1%,化合物B为93.3%–114.5%,化合物C两个最高剂量组为92.0%–96.7%。
  • Cmax几何均值比处于相同范围,基于咪达唑仑微剂量结果未发现相关药物相互作用。
  • 这些研究中AUC2-4比值与AUC0-∞比值相当。

临床怎么用

  • 在早期临床研究中可嵌入75 μg咪达唑仑微剂量以评估CYP3A药物相互作用潜力,减少专项DDI研究。
  • 可考虑采用有限采样(如AUC2-4)替代完整AUC0-∞以降低受试者负担、成本和资源需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: We aimed to incorporate a pharmacologically inactive midazolam microdose into early clinical studies for the assessment of CYP3A drug-drug interaction liability. METHODS: Three early clinical studies were conducted with substances (Compounds A, B and C) which gave positive CYP3A perpetrator signals in vitro. A 75 μg dose of midazolam was administered alone (baseline CYP3A activity) followed by administration with the highest dose groups tested for each compound on Day 1/3 and Day 14 or Day 17. Midazolam exposure (AUC0-∞ , Cmax ) during administration with the test substances was compared to baseline data via an analysis of variance on log-transformed data. Partial AUC2-4 ratios were also compared to AUC0-∞ ratios using linear regression on log-transformed data. RESULTS: Test compound Cmax values exceeded relevant thresholds for drug-drug interaction liability. Midazolam concentrations were quantifiable over the full profiles for all subjects in all studies. Point estimates of the midazolam AUC0-∞ gMean ratios ranged from 108.3 to 127.1% for Compound A, from 93.3 to 114.5% for Compound B, and from 92.0 to 96.7% for the two highest dose groups of Compound C. Cmax gMean ratios were in the same range. Thus, no relevant drug-drug interactions were evident, based on the results of midazolam microdosing. AUC2-4 ratios from these studies were comparable to the AUC0-∞ ratios. CONCLUSION: Midazolam microdosing incorporated into early clinical studies is a feasible tool for reducing dedicated drug-drug interaction studies, meaning reduced subject burden. Limited sampling could further reduce subject burden, costs and needed resources.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Wiebe ST, Huennemeyer A, Kadus W, et al. Midazolam microdosing applied in early clinical development for drug-drug interaction assessment. Br J Clin Pharmacol. 2020. PMID: 32436239. doi:10.1111/bcp.14389

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。